- Home
- GORO vs CRDF Comparison
GORO vs CRDF Comparison
Compare GORO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GORO | CRDF |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 187.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GORO | CRDF |
|---|---|---|
| Price | $1.60 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.75 | ★ $10.83 |
| AVG Volume (30 Days) | ★ 11.7M | 1.3M |
| Earning Date | 11-04-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,430,000.00 | $501,000.00 |
| Revenue This Year | $8.76 | N/A |
| Revenue Next Year | $85.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.29 | $1.85 |
| 52 Week High | $1.87 | $4.99 |
Technical Indicators
Market Signals| Indicator | GORO | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 65.74 | 26.08 |
| Support Level | $0.95 | $2.72 |
| Resistance Level | $1.87 | $3.05 |
| Average True Range (ATR) | 0.21 | 0.19 |
| MACD | 0.06 | -0.14 |
| Stochastic Oscillator | 71.37 | 0.90 |
Price Performance
Historical ComparisonAbout GORO Gold Resource Corporation
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.